PERFORM Publications

Keyword search (4,163 papers available)

Title		Authors	PubMed ID
1	Sleep neuroimaging: Review and future directions	Pereira M; Chen X; Paltarzhytskaya A; Pache?o Y; Muller N; Bovy L; Lei X; Chen W; Ren H; Song C; Lewis LD; Dang-Vu TT; Czisch M; Picchioni D; Duyn J; Peigneux P; Tagliazucchi E; Dresler M;	39940102 HKAP
2	Brain PET Imaging in Small Animals: Tracer Formulation, Data Acquisition, Image Reconstruction, and Data Analysis	Bdair H; Kang MS; Ottoy J; Aliaga A; Kunach P; Singleton TA; Blinder S; Soucy JP; Leyton M; Rosa-Neto P; Kostikov A;	38006502 PERFORM
3	Bayesian workflow for the investigation of hierarchical classification models from tau-PET and structural MRI data across the Alzheimer's disease spectrum	Belasso CJ; Cai Z; Bezgin G; Pascoal T; Stevenson J; Rahmouni N; Tissot C; Lussier F; Rosa-Neto P; Soucy JP; Rivaz H; Benali H;	37920382 PERFORM
4	Dosimetry of [18F]TRACK, the first PET tracer for imaging of TrkB/C receptors in humans	Thiel A; Kostikov A; Ahn H; Daoud Y; Soucy JP; Blinder S; Jaworski C; Wängler C; Wängler B; Juengling F; Enger SA; Schirrmacher R;	37870640 PERFORM
5	Radiosynthesis and In Vivo Evaluation of Four Positron Emission Tomography Tracer Candidates for Imaging of Melatonin Receptors	Bdair H; Singleton TA; Ross K; Jolly D; Kang MS; Aliaga A; Tuznik M; Kaur T; Yous S; Soucy JP; Massarweh G; Scott PJH; Koeppe R; Spadoni G; Bedini A; Rudko DA; Gobbi G; Benkelfat C; Rosa-Neto P; Brooks AF; Kostikov A;	35420022 PERFORM
6	Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment	Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, Chamoun M, Tissot C, Lussier F, Mohaddes S, Soucy JP, Massarweh G, Gauthier S, Rosa-Neto P,	32582834 PERFORM
7	Chronic Neuroleptic-Induced Parkinsonism Examined with Positron Emission Tomography.	Galoppin M, Berroir P, Soucy JP, Suzuki Y, Lavigne GJ, Gagnon JF, Montplaisir JY, Stip E, Blanchet PJ	32353194 PERFORM
8	Development of "[11C]kits" for a fast, efficient and reliable production of carbon-11 labeled radiopharmaceuticals for Positron Emission Tomography.	Jolly D, Hopewell R, Kovacevic M, Li QY, Soucy JP, Kostikov A	28038410 PERFORM
9	Impaired sensorimotor processing during complex gait precedes behavioral changes in middle-aged adults.	Mitchell T, Starrs F, Soucy JP, Thiel A, Paquette C	30247510 PERFORM

Title:	Chronic Neuroleptic-Induced Parkinsonism Examined with Positron Emission Tomography.
Authors:	Galoppin M, Berroir P, Soucy JP, Suzuki Y, Lavigne GJ, Gagnon JF, Montplaisir JY, Stip E, Blanchet PJ
Link:	https://www.ncbi.nlm.nih.gov/pubmed/32353194?dopt=Abstract
DOI:	10.1002/mds.28046
Publication:	Movement disorders : official journal of the Movement Disorder Society
Keywords:	antipsychotic drugs; dihydrotetrabenazine; positron emission tomography; raclopride; striatum;
PMID:	32353194	Category:	Mov Disord	Date Added:	2020-05-01
Dept Affiliation:	PERFORM 1 Department of Medicine, University of Montreal Hospital Center, Montreal, Canada. 2 PERFORM Centre, Concordia University, Montreal, Canada. 3 McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada. 4 Department of Stomatognathic Function and Occlusal Reconstruction, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan. 5 Centre for Advanced Research in Sleep Medicine, Hopital du Sacre-Coeur de Montreal, Montreal, Canada. 6 Faculty of Dental Medicine, University of Montreal, Montreal, Canada. 7 Department of Psychiatry, United Arab Emirates University, Al Ain, United Arab Emirates. 8 Montreal Mental Health University Institute, Montreal, Canada.

Description:

Chronic Neuroleptic-Induced Parkinsonism Examined with Positron Emission Tomography.

Mov Disord. 2020 Apr 30;:

Authors: Galoppin M, Berroir P, Soucy JP, Suzuki Y, Lavigne GJ, Gagnon JF, Montplaisir JY, Stip E, Blanchet PJ

Abstract

BACKGROUND: Neuroleptic drug-induced parkinsonism (NIP) is a leading cause of parkinsonism, particularly in aging. Based on abnormal dopamine transporter scan results, individuals displaying chronic NIP are often diagnosed with Lewy-body Parkinson's disease (PD), but this assumption needs further substantiation.

OBJECTIVE: To quantitate the profile of striatal dopaminergic nerve terminal density in NIP relative to PD.

METHODS: We used the positron emission tomography ligand [11 C](+)-dihydrotetrabenazine targeting vesicular monoamine transporter type 2 (VMAT2) binding sites and collected various clinical parameters (motor ratings, olfaction, polysomnography to document rapid eye movement sleep muscle activity, quantitative sensory testing for pain thresholds) possibly predicting binding results in patients older than age 50 living with schizophrenia spectrum disorders under long-term stable antipsychotic drug treatment, with (N = 11) or without (N = 11) chart documention of chronic NIP, and compared them to healthy volunteers (N = 11) and others medicated for PD (N = 12).

RESULTS: Striatal VMAT2 binding was dichotomous in the NIP group between those with spared (N = 5) or low (N = 6) PD-like values. Striatal binding reduction in the low VMAT2-NIP group was asymmetric without the gradient of maximal involvement in the posterior putamen typical of PD. Anosmia was the only nonmotor parameter measured matching the abnormal striatal VMAT2 binding status.

CONCLUSION: These preliminary observations suggest that striatal VMAT2 binding is abnormal in a fraction of chronic NIP cases and differs in spatial distribution from PD. The possibility of a drug-induced axonopathy and resultant synaptopathy, as well as the evolution of the binding deficit, warrant further longitudinal studies in a large cohort. © 2020 International Parkinson and Movement Disorder Society.

PMID: 32353194 [PubMed - as supplied by publisher]

BookR: School of Health Core Facilities Booking

"positron emission tomography" Keyword-tagged Publications:

Search Publications

No results